Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) fell 2.8% during mid-day trading on Tuesday . The company traded as low as $61.70 and last traded at $62.04. 200,522 shares were traded during mid-day trading, an increase of 6% from the average session volume of 189,291 shares. The stock had previously closed at $63.82.
Gemini Therapeutics Trading Down 2.8 %
The firm has a 50-day moving average of $62.17 and a 200 day moving average of $52.47. The stock has a market capitalization of $2.69 billion, a price-to-earnings ratio of -62.04 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
- Five stocks we like better than Gemini Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Business Services Stocks Investing
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
